# Exact Sciences Corporation clinical trials: 31 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 31 trials with Exact Sciences Corporation as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Exact Sciences Corporation: 31 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/exact-sciences-corporation

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 31
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 31, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 22, 2026 | NCT07544680 | Endometrial Cancer Vaginal Fluid Specimen Collection Study | Exact Sciences Corporation | Observational | Active not recruiting | Abnormal Uterine Bleeding (AUB), Endometrial Cancer, Atypical Endometrial Hyperplasia, Endometrial Hyperplasia With... | 4,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07544680) |
| September 19, 2024 | NCT06589310 | Falcon Real World Evidence Registry | Exact Sciences Corporation | Observational | Recruiting | Cancer | 25,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06589310) |
| May 6, 2024 | NCT06401421 | EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD) | Exact Sciences Corporation | Observational | Recruiting | Breast Cancer | 1,800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06401421) |
| May 3, 2024 | NCT06398743 | First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer | Exact Sciences Corporation | Observational | Active not recruiting | Colorectal Cancer | 416 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06398743) |
| February 18, 2022 | NCT05246839 | Informed Choice - Compass | Exact Sciences Corporation | Observational | Terminated | Colorectal Cancer | 1,823 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05246839) |
| January 27, 2022 | NCT05210283 | CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer | Exact Sciences Corporation | Observational | Active not recruiting | Colorectal Cancer | 1,017 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05210283) |
| October 1, 2021 | NCT05064553 | ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk | Exact Sciences Corporation | Observational | Active not recruiting | Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer | 2,990 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05064553) |
| July 16, 2020 | NCT04473625 | Stool Collection Sub-Study of Exact Sciences Protocol 2018-01 | Exact Sciences Corporation | Observational | Completed | Colorectal Cancer, Colo-rectal Cancer, Cancer | 291 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04473625) |
| May 20, 2020 | NCT04395391 | Home Usability Study of the SARS-CoV-2 (COVID-19) Test | Exact Sciences Corporation | Observational | Completed | COVID-19 | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04395391) |
| December 30, 2019 | NCT04213326 | Detecting Cancers Earlier Through Elective Plasma-based CancerSEEK Testing | Exact Sciences Corporation | Observational | Completed | Early Cancer Detection | 6,400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04213326) |
| October 30, 2019 | NCT04144751 | Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: "Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0)... | Exact Sciences Corporation | Observational | Completed | Colorectal Cancer | 23,494 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04144751) |
| October 30, 2019 | NCT04144738 | Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening "BLUE-C" | Exact Sciences Corporation | Observational | Completed | Colorectal Cancer | 26,758 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04144738) |
| October 11, 2019 | NCT04124406 | Voyage: Real-World Impact of the Multi-target Stool DNA Test on CRC Screening and Mortality | Exact Sciences Corporation | Observational | Active not recruiting | Colon Cancer | 150,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04124406) |
| January 30, 2019 | NCT03821948 | Blood and Stool Sample Collection in Subjects Participating in Colorectal Cancer Screening: Act Bold | Exact Sciences Corporation | Observational | Completed | Colorectal Cancer | 5,131 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03821948) |
| December 28, 2018 | NCT03789162 | Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast | Exact Sciences Corporation | Observational | Completed | Colorectal Cancer | 850 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03789162) |
| November 14, 2018 | NCT03741166 | Blood Collection Sub-Study for CRC Screening in Individuals 45-49 at Average Risk for CRC. | Exact Sciences Corporation | Observational | Completed | Colo-rectal Cancer | 871 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03741166) |
| November 2, 2018 | NCT03728348 | An Evaluation of a Multi-target Stool DNA (Mt-sDNA) Test, Cologuard, for CRC Screening in Individuals Aged 45-49 and at Average Risk for... | Exact Sciences Corporation | Observational | Completed | Colorectal Cancer | 983 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03728348) |
| November 1, 2018 | NCT03727087 | Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Melanoma | Exact Sciences Corporation | Observational | Terminated | Melanoma | 348 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03727087) |
| November 1, 2018 | NCT03727009 | Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies | Exact Sciences Corporation | Observational | Terminated | Hematologic Malignancy | 409 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03727009) |
| October 15, 2018 | NCT03705013 | Observational Study of Sub-populations From Cologuard Post-Approval Study (2014-01) | Exact Sciences Corporation | Observational | Terminated | Colorectal Cancer | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03705013) |
| September 7, 2018 | NCT03662204 | Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors | Exact Sciences Corporation | Observational | Completed | Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Bladder Cancer, Uterine Cancer, Kidney Cancer, Renal... | 5,133 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03662204) |
| August 16, 2018 | NCT03633006 | Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer | Exact Sciences Corporation | Observational | Completed | Lung Cancer (Diagnosis) | 3,298 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03633006) |
| August 14, 2018 | NCT03628651 | Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma | Exact Sciences Corporation | Observational | Completed | Hepatocellular Carcinoma, Hepatocellular Carcinoma Surveillance | 2,150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03628651) |
| August 14, 2018 | NCT03628638 | Blood Sample Collection in Subjects Participating in a Lung Cancer Screening Program | Exact Sciences Corporation | Observational | Completed | Healthy | 1,718 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03628638) |
| July 21, 2015 | NCT02503696 | Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD) | Exact Sciences Corporation | Observational | Completed | Inflammatory Bowel Disease, Colorectal Neoplasms, Digestive System Diseases, Colonic Diseases, Colorectal Cancer | 697 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02503696) |

## By phase

| Phase | Trials |
| --- | --- |
| Observational | 31 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 19 |
| Terminated | 5 |
| Active not recruiting | 5 |
| Recruiting | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Colorectal Neoplasms | 18 |
| Neoplasms | 8 |
| Digestive System Diseases | 6 |
| Colonic Diseases | 6 |
| Intestinal Neoplasms | 6 |
| Gastrointestinal Neoplasms | 6 |
| Digestive System Neoplasms | 6 |
| Neoplasms by Site | 6 |
| Gastrointestinal Diseases | 6 |
| Intestinal Diseases | 6 |
| Rectal Diseases | 5 |
| Colonic Neoplasms | 3 |
| Breast Neoplasms | 2 |
| Lung Neoplasms | 2 |
| Liver Neoplasms | 2 |
| Inflammatory Bowel Diseases | 2 |
| Carcinoma, Hepatocellular | 2 |
| Hematologic Neoplasms | 1 |
| Prostatic Neoplasms | 1 |
| Urinary Bladder Neoplasms | 1 |
| Uterine Neoplasms | 1 |
| Kidney Neoplasms | 1 |
| Pancreatic Neoplasms | 1 |
| Stomach Neoplasms | 1 |
| Ovarian Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Freight forwarders in the United States](https://specstream.ai/data/businesses/freight-forwarders/united-states)
- [Manufacturing consultants in the United States](https://specstream.ai/data/businesses/manufacturing-consultants/united-states)
- [Psychiatry practices in the United States](https://specstream.ai/data/businesses/psychiatry-practices/united-states)
- [Ukrainian restaurants in the United States](https://specstream.ai/data/businesses/ukrainian-restaurants/united-states)
- [Bankruptcy law firms in the United States](https://specstream.ai/data/businesses/bankruptcy-law-firms/united-states)
- [Document shredding companies in the United States](https://specstream.ai/data/businesses/document-shredding-companies/united-states)
